Bill
S 4587
Overview: Senate Bill S 4587 relates to prescription labels for mifepristone and misoprostol.Purpose and Intent: The bill aims to require specific labeling and instructions on pres
Overview: Senate Bill S 4587 relates to prescription labels for mifepristone and misoprostol.
Purpose and Intent: The bill aims to require specific labeling and instructions on prescriptions for the medications mifepristone and misoprostol, which are used for medication abortion. The goal is to ensure patients receive clear information about the proper use and potential side effects of these drugs.
Key Provisions:
- Mandates that prescription labels for mifepristone and misoprostol include the following information:
- The name of the medication and its purpose
- Detailed instructions for proper use
- Warnings about potential side effects and complications
- Requires the label to be written in plain language and available in multiple languages.
- Directs the Department of Health to develop standardized label requirements and patient information materials.
Affected Parties and Impacts: The bill would impact individuals prescribed mifepristone and misoprostol, as well as healthcare providers who prescribe and dispense these medications. Clearer labeling and instructions could help ensure patients use the drugs safely and effectively.
Procedural and Timeline Considerations: This bill has been substituted by Assembly Bill A5285, which is currently under consideration. If passed, the new labeling requirements would need to be implemented by the Department of Health in a timely manner.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
